Literature DB >> 28571205

Postoperative Malignant Hyperthermia- A Medical Emergency: A Case Report and Review of Literature.

Amit Kumar Sinha1, Poonam Kumari2, Maheshkumar Manilal Vaghela1, Chandni Sinha3, Bindey Kumar4.   

Abstract

Malignant hyperthermia is a rare life threatening pharmacological disorder. Preoperative clinical diagnosis is not possible. Due to its rarity and severity, it must be taken as an important differential diagnosis for postoperative hyperthermia. We hereby report a case of postoperative malignant hyperthermia in a four-year-old female child, who was operated for type 1 choledochal cyst and had difficult postoperative sequel. We lost that child due to unavailability of Dantrolene sodium in emergency drug cart.

Entities:  

Keywords:  Dantrolene sodium; Myoglobinuria; Postsurgery

Year:  2017        PMID： 28571205      PMCID： PMC5449851          DOI： 10.7860/JCDR/2017/20531.9493

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  10 in total

1.  Benign hyperthermia following prolonged TIVA with propofol.

Authors:  H Fukayama; H Kohase; M Umino
Journal:  Can J Anaesth       Date:  2000-11       Impact factor: 5.063

2.  Combined anesthetic- and stress-induced malignant hyperthermia in two offspring of malignant hyperthermic-susceptible parents.

Authors:  B A Britt
Journal:  Anesth Analg       Date:  1988-04       Impact factor: 5.108

3.  Markedly delayed postoperative malignant hyperthermia.

Authors:  C R Souliere; S J Weintraub; J C Kirchner
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1986-05

4.  Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.

Authors:  M R Weglinski; D J Wedel; A G Engel
Journal:  Anesth Analg       Date:  1997-05       Impact factor: 5.108

5.  The effects of dantrolene on the contraction, relaxation, and energetics of the diaphragm muscle.

Authors:  O Langeron; C Coirault; S Fratea; G Orliaguet; P Coriat; B Riou
Journal:  Anesth Analg       Date:  1999-08       Impact factor: 5.108

6.  Failure of lidocaine to trigger porcine malignant hyperthermia.

Authors:  D W Wingard; S Bobko
Journal:  Anesth Analg       Date:  1979 Mar-Apr       Impact factor: 5.108

7.  Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry.

Authors:  Priscilla Nelson; Ronald S Litman
Journal:  Anesth Analg       Date:  2014-02       Impact factor: 5.108

8.  A clinical grading scale to predict malignant hyperthermia susceptibility.

Authors:  M G Larach; A R Localio; G C Allen; M A Denborough; F R Ellis; G A Gronert; R F Kaplan; S M Muldoon; T E Nelson; H Ording
Journal:  Anesthesiology       Date:  1994-04       Impact factor: 7.892

9.  Dantrolene blocks intracellular calcium release in smooth muscle: competitive antagonism of thromboxane A2.

Authors:  A I Ally; D F Horrobin; M S Manku; R O Morgan; M Karmazyn; R A Karmali; S C Cunnane
Journal:  Can J Physiol Pharmacol       Date:  1978-06       Impact factor: 2.273

10.  Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry.

Authors:  Ronald S Litman; Christopher D Flood; Richard F Kaplan; Yung Ly Kim; Joseph R Tobin
Journal:  Anesthesiology       Date:  2008-11       Impact factor: 7.892
  10 in total
  2 in total

1.  Mice with R2509C-RYR1 mutation exhibit dysfunctional Ca2+ dynamics in primary skeletal myocytes.

Authors:  Yoshitaka Tsuboi; Kotaro Oyama; Fuyu Kobirumaki-Shimozawa; Takashi Murayama; Nagomi Kurebayashi; Toshiaki Tachibana; Yoshinobu Manome; Emi Kikuchi; Satoru Noguchi; Takayoshi Inoue; Yukiko U Inoue; Ichizo Nishino; Shuichi Mori; Ryosuke Ishida; Hiroyuki Kagechika; Madoka Suzuki; Norio Fukuda; Toshiko Yamazawa
Journal:  J Gen Physiol       Date:  2022-10-06       Impact factor: 4.000

2.  A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.

Authors:  Toshiko Yamazawa; Takuya Kobayashi; Nagomi Kurebayashi; Masato Konishi; Satoru Noguchi; Takayoshi Inoue; Yukiko U Inoue; Ichizo Nishino; Shuichi Mori; Hiroto Iinuma; Noriaki Manaka; Hiroyuki Kagechika; Arkady Uryash; Jose Adams; Jose R Lopez; Xiaochen Liu; Christine Diggle; Paul D Allen; Sho Kakizawa; Keigo Ikeda; Bangzhong Lin; Yui Ikemi; Kazuto Nunomura; Shinsaku Nakagawa; Takashi Sakurai; Takashi Murayama
Journal:  Nat Commun       Date:  2021-07-13       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.